Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Seshadri Kasturi

Urogynecology and Reconstructive Pelvic Surgery Sacramento, CA Medical Doctor

NPI 1154555340 CMS profile 7572

2801 K St, Suite 200, Sacramento, CA 95816

Open in the dashboard

General payments

$35,703

257 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Seshadri Kasturi of Sacramento, CA is reported in the CMS Open Payments database as having received $35,703 across 257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $318 13
2024 General $13,104 48
2023 General $587 23
2022 General $9,476 30
2021 General $6,715 47
2020 General $4,880 46
2019 General $624 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seshadri Kasturi
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Seshadri Kasturi were reported at $318. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Seshadri Kasturi Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $624 $799 $319–$2,013 $163
2020 $4,880 $384 $158–$1,360 $114
2021 $6,715 $641 $247–$2,515 $132
2022 $9,476 $843 $347–$2,794 $149
2023 $587 $819 $308–$2,302 $160
2024 $13,104 $882 $306–$2,459 $164
2025 $318 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $32,049 49 payments
  2. Pfizer Inc. $738 65 payments
  3. Allergan Inc. $472 21 payments
  4. AbbVie, Inc. $348 19 payments
  5. Astellas Pharma US Inc $304 13 payments
  6. Sumitomo Pharma America, Inc. $283 16 payments
  7. Boston Scientific Corporation $249 9 payments
  8. Urovant Sciences Inc $215 11 payments
  9. Caldera Medical, Inc $183 4 payments
  10. TherapeuticsMD, Inc. $158 16 payments
  11. Other $704 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,279 4 payments
  2. Education $9,590 15 payments
  3. Food and Beverage $4,606 224 payments
  4. Travel and Lodging $3,199 13 payments
  5. Gift $29 1 payment
Products named General payments · program years 2019–2025
  1. Altis Women's Health $27,428 33 payments
  2. ALTIS Female Incontinence $4,000 1 payment
  3. PREMARIN $702 62 payments
  4. GEMTESA $498 27 payments
  5. BOTOX Hyperhydrosis $307 19 payments
  6. FEMALE INCONTINENCE $226 2 payments
  7. BOTOX Urology $224 5 payments
  8. MYRBETRIQ $222 12 payments
  9. BOTOX Botox Therapeutic $206 11 payments
  10. Desara $164 3 payments
  11. Other $1,774 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,862

Median for Undefined Physician type: 319

Drug cost

$229,878

Median for Undefined Physician type: $28,032

Branded share of claims

61.3%

Median for Undefined Physician type: 24.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 289 $141,428
Gemtesa Vibegron Brand 48 $43,215
Premarin Estrogens, Conjugated Brand 27 $11,663
Estradiol Generic 135 $7,988
Trospium Chloride Er Trospium Chloride Brand 57 $6,441
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 353 $5,524
Imvexxy Estradiol Brand 15 $4,800
Fosfomycin Tromethamine Generic 12 $1,477
Cephalexin Generic 290 $1,390
Oxybutynin Chloride Er Oxybutynin Chloride Brand 58 $1,062

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 138 Part D prescribers listed as Undefined Physician type; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$857,034

Of which drugs: $159,514

Medicare patients

1,099

Average age 75

Services billed

32,854

1,099 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 61%
Osteoporosis 28%
Depression 26%
Diabetes 24%
Chronic kidney disease 21%
Ischemic heart disease 18%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 118 26,300 $130,480
Injection, dmso, dimethyl sulfoxide, 50%, 50 ml J1212 Office 13 53 $28,969
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 25 $18
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 15 49 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $180
$180 — 26,300
GEMTESA
  • Sumitomo Pharma America, Inc. $66
$66 48 —
Xeomin
  • MERZ NORTH AMERICA, INC. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record